139 related articles for article (PubMed ID: 35975106)
1. GNPNAT1 Predicts Poor Prognosis and Cancer Development in Non-Small Cell Lung Cancer.
Feng Y; Li N; Ren Y
Cancer Manag Res; 2022; 14():2419-2428. PubMed ID: 35975106
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of GNPNAT1 Predicts Poor Prognosis and Correlates With Immune Infiltration in Lung Adenocarcinoma.
Liu W; Jiang K; Wang J; Mei T; Zhao M; Huang D
Front Mol Biosci; 2021; 8():605754. PubMed ID: 33842535
[TBL] [Abstract][Full Text] [Related]
3. Independent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma.
Zheng X; Li Y; Ma C; Zhang J; Zhang Y; Fu Z; Luo H
Biomed Res Int; 2020; 2020():8851437. PubMed ID: 33178836
[TBL] [Abstract][Full Text] [Related]
4. Glucosamine-phosphate N-acetyltransferase 1 and its DNA methylation can be biomarkers for the diagnosis and prognosis of lung cancer.
Ding P; Peng B; Li G; Sun X; Wang G
J Clin Lab Anal; 2022 Sep; 36(9):e24628. PubMed ID: 35929347
[TBL] [Abstract][Full Text] [Related]
5. GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer.
Yuan R; Zhang Y; Wang Y; Chen H; Zhang R; Hu Z; Chai C; Chen T
Front Immunol; 2023; 14():1152678. PubMed ID: 37215111
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of glucosamine-phosphate N-acetyltransferase 1 is a promising diagnostic and predictive indicator for poor survival in patients with lung adenocarcinoma.
Zhu P; Gu S; Huang H; Zhong C; Liu Z; Zhang X; Wang W; Xie S; Wu K; Lu T; Zhou Y
Oncol Lett; 2021 Jun; 21(6):488. PubMed ID: 33968204
[TBL] [Abstract][Full Text] [Related]
7. Potential role of glucosamine-phosphate N-acetyltransferase 1 in the development of lung adenocarcinoma.
Zhang S; Zhang H; Li H; Guo J; Wang J; Zhang L
Aging (Albany NY); 2021 Mar; 13(5):7430-7453. PubMed ID: 33686019
[TBL] [Abstract][Full Text] [Related]
8. GNPNAT1 promotes the stemness of breast cancer and serves as a potential prognostic biomarker.
Hu H; Wang ZW; Hu S; Xiang Y; Deng Y; Wan FJ; Zhang TC; Yang ZY; Liao XH
Oncol Rep; 2023 Aug; 50(2):. PubMed ID: 37387422
[TBL] [Abstract][Full Text] [Related]
9. Novel form of rhizomelic skeletal dysplasia associated with a homozygous variant in
Ain NU; Baroncelli M; Costantini A; Ishaq T; Taylan F; Nilsson O; Mäkitie O; Naz S
J Med Genet; 2021 May; 58(5):351-356. PubMed ID: 32591345
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway.
Zhu W; Shi L; Gong Y; Zhuo L; Wang S; Chen S; Zhang B; Ke B
Thorac Cancer; 2022 Apr; 13(7):1027-1039. PubMed ID: 35178875
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of FGF19 predicts poor prognosis in patients with non-small cell lung cancer.
Chen J; Shao J; Shen A; Zhu X; Zhang X; Sun H; Wei S; Ling Y
J Thorac Dis; 2021 Mar; 13(3):1769-1784. PubMed ID: 33841967
[TBL] [Abstract][Full Text] [Related]
12. HNRNPD is a prognostic biomarker in non-small cell lung cancer and affects tumor growth and metastasis via the PI3K-AKT pathway.
Fan G; Li D; Liu J; Tao N; Meng C; Cui J; Cai J; Sun T
Biotechnol Genet Eng Rev; 2023 Mar; ():1-20. PubMed ID: 36971333
[TBL] [Abstract][Full Text] [Related]
13. Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in non-small cell lung cancer that drives the EMT phenotype.
Zhang L; Zhang J; Ma Y; Chen J; Dong B; Zhao W; Wang X; Zheng Q; Fang F; Yang Y
Lung Cancer; 2015 Sep; 89(3):320-8. PubMed ID: 26144287
[TBL] [Abstract][Full Text] [Related]
14. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
[TBL] [Abstract][Full Text] [Related]
15. ZNF671 Inhibits the Proliferation and Metastasis of NSCLC via the Wnt/β-Catenin Pathway.
Zhan W; Li Y; Liu X; Zheng C; Fu Y
Cancer Manag Res; 2020; 12():599-610. PubMed ID: 32158264
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Cui D; Yu CH; Liu M; Xia QQ; Zhang YF; Jiang WL
Tumour Biol; 2016 Mar; 37(3):4127-34. PubMed ID: 26490983
[TBL] [Abstract][Full Text] [Related]
17. PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway.
Bai Y; Liu X; Qi X; Liu X; Peng F; Li H; Fu H; Pei S; Chen L; Chi X; Zhang L; Zhu X; Song Y; Wang Y; Meng S; Jiang T; Shao S
EBioMedicine; 2019 Apr; 42():311-325. PubMed ID: 30922965
[TBL] [Abstract][Full Text] [Related]
18. Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.
Zhou L; Yu L; Zhu B; Wu S; Song W; Gong X; Wang D
BMC Cancer; 2016 Nov; 16(1):876. PubMed ID: 27832750
[TBL] [Abstract][Full Text] [Related]
19. SMYD3 overexpression indicates poor prognosis and promotes cell proliferation, migration and invasion in non‑small cell lung cancer.
Li J; Zhao L; Pan Y; Ma X; Liu L; Wang W; You W
Int J Oncol; 2020 Sep; 57(3):756-766. PubMed ID: 32705243
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.
Tang Y; Luo J; Zhou Y; Zang H; Yang Y; Liu S; Zheng H; Ma J; Fan S; Wen Q
BMC Cancer; 2022 May; 22(1):564. PubMed ID: 35596155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
